Westinghouse and Chantilly-based Amentum are building a repeatable delivery model for AP1000 reactors and the AP300 small modular reactor.

Pittsburgh's Kamin Science Center is opening a three-story electric go-kart track with 40-mph daytime races and adults-only night sessions.

Jacobian and Mine Vision Systems picked Bakery Square for new headquarters, boosting the Penn Avenue 'AI Avenue' tech corridor.

A WVU‑led coalition won a $321M NSF Regional Innovation Engines award to build an industrial energy hub in Appalachia focused on grid resilience, startups and jobs.

Allegheny Health Network says Allegheny General Hospital completed the Pittsburgh region’s first robotic-assisted kidney transplant, offering a less-invasive option for select patients.

Carnegie Mellon is pulling together StartUP PGH, a Sept. 14–18 week that will bundle AI, robotics and life‑science showcases to bring investors to Pittsburgh.

After a 14‑month collaboration, Panther Life Sciences will establish a manufacturing and materials unit in Pittsburgh after validating production at Pitt’s BioForge. The move boosts Hazelwood Green’s biotech pipeline.

PSC secured a $10M NSF award to build Bridges-3, a next-gen supercomputer planned to go live in summer 2027 and designed to boost AI and large-data research in Pittsburgh.

UPMC Presbyterian is using a bedside blood test that spots brain‑injury biomarkers in about 15 minutes, aimed at cutting CT scans and speeding ER care.

Allegheny General’s Mario Lemieux Center has opened a newly renovated $19M cath lab, bringing pulsed‑field ablation and upgraded electrophysiology tools to the North Side.

The Army and Carnegie Mellon staged a robotics and autonomy forum at CMU’s new RIC this week, underscoring Pittsburgh’s bid to attract defense‑tech contracts and jobs.

Pitt researchers turned a harmless eye bacterium into a prototype "living eye drop" that secretes anti-inflammatory IL-10 and sped cornea healing in mice. The proof-of-concept could reduce repeated dosing, but human trials are still distant.

A Pitt study suggests early teen experimentation may be driven by lower dopamine‑related brain markers, not an oversupply of reward chemistry. The finding points to a prevention window in adolescence.